AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Moderna covid 19 vaccine production capacity10/13/2023 Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are statements that are not historical facts. Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Media Relations Contacts Ashleigh Koss Tel: +1 (908) 205-2572 Sandrine Guendoul Tel.: +33 (0)1 53 77 46 46 Nicolas Kressmann Tel.: +1 (732) 532 53-18 Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco IR main line: Tel.: +33 (0)1 53 77 45 45 With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We are a global biopharmaceutical company focused on human health. About Sanofi Sanofi is dedicated to supporting people through their health challenges. In March 2021, Sanofi and Translate Bio initiated a Phase 1/2 clinical trial of their mRNA COVID-19 vaccine candidate, in order to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels.įind out more about our COVID-19 vaccine candidates. In addition to the recombinant protein-based vaccine in collaboration with GSK, Sanofi is developing a messenger RNA vaccine in partnership with Translate Bio.This effort is supported by the United States’ Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response under contract W15QKN-16-9-1002. This vaccine is anticipated to be available in Q4 2021 pending Phase 3 outcomes and regulatory authorizations. Enrollment of total 720 participants was completed on March 8 and results are expected in Q2 2021. On February 22, 2021, Sanofi and GSK announced the beginning of a new Phase 2 study with an improved antigen formulation. Sanofi is collaborating with GSK on a COVID-19 vaccine candidate using the same recombinant protein-based manufacturing technology as one of Sanofi’s seasonal influenza vaccines, combined with GSK’s established pandemic adjuvant platform.Sanofi continues to prioritize develop ment of its two COVID-19 vaccine candidates Sanofi continues to be actively involved in discussions with governments and organizations to identify additional areas of pandemic response where the company can make a meaningful impact. Sanofi is the only large manufacturer to support all three vaccine efforts. In February, Sanofi announced one of its manufacturing site in France would support Johnson & Johnson for the production of its COVID-19 vaccine at a rate of approximately 12 million doses per month. Earlier this year, Sanofi announced the company will provide support to BioNTech for 125 million doses for the European Union. This marks Sanofi’s third commitment to provide manufacturing support. I would also like to acknowledge the contributions of the Department of Health and Human Services, and the Biden administration, to facilitate this new partnership. “ We are one of the few pharmaceutical c ompanies to leverage many industrial partnerships to improve global supply and access to COVID-19 vaccines, while in parallel, also continuing to develop our two COVID-19 vaccine programs. “ Since the beginning of the pandemic, we have been mobilizing on multiple fronts and we show ed solidarity across the industry ”, said Paul Hudson, Chief Executive Officer, Sanofi. Sanofi will leverage its established infrastructure and manufacturing expertise at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Moderna’s COVID-19 vaccine, starting in September 2021. Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine supply needs.
0 Comments
Read More
Leave a Reply. |